CHICAGO — In this Healio Video Perspective from the AAO meeting, Brandon D. Ayres, MD, of Wills Eye Hospital discusses a study exploring the impact of Cequa on patients with dry eye disease who were previously treated with Restasis.
The phase 4 study enrolled patients who were not fully satisfied with Restasis (cyclosporine ophthalmic emulsion 0.05%, Allergan) results who were then switched to Cequa (cyclosporine ophthalmic solution 0.09%, Sun Pharmaceutical).
“Interestingly, within a month, they saw significant improvement in not only corneal staining but also the modified [Symptom